Ronald Blue Trust, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.98 Billion
- Q3 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 24 shares of SUPN stock, worth $905. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24Holding current value
$905% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
283Shares Held
60.8MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$231 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$192 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$109 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$99.3 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.02B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...